Breaking News, Collaborations & Alliances

Biogen, Isis in Neurological Collaboration

Will leverage antisense technology to advance therapies for neurological disorders

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec and Isis Pharmaceuticals have entered into a multi-year collaboration to advance the treatment of neurological diseases. The agreement combines Biogen’s expertise in neurology with Isis’ antisense technology to develop novel therapies. As part of the six-year research collaboration, Biogen will gain exclusive rights to Isis’ antisense technology to develop therapies for neurological diseases.   Biogen Idec will make an upfront payment of $100 million and Isis is eli...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters